Increases in Psychological Flexibility Mediate Relationship Between Acute Psychedelic Effects and Decreases in Racial Trauma Symptoms Among People of Color

The paper frames racial trauma as a prevalent but under-researched form of trauma experienced by people of colour (POC), characterised by repeated or acute race-based threats that can contribute to PTSD symptoms and broader mental-health burden. The authors note that existing evidence-based PTSD treatments have limited inclusion of POC and that treatment dropout is high in these groups, highlighting a gap in culturally inclusive interventions. Parallel literatures on psychedelic compounds (for example psilocybin, LSD, and MDMA) indicate they can reduce depression and anxiety and that the intensity of acute subjective effects (mystical-type, insight, challenging) often predicts therapeutic benefit; however, clinical psychedelic trials have largely lacked racial and ethnic diversity. Davis and colleagues therefore set out to test whether changes in psychological flexibility mediate the relationship between acute psychedelic effects and reductions in racial trauma symptoms among Black, Indigenous, and people of colour (BIPOC). Drawing on prior survey and prospective work—largely in predominantly White samples—that linked acute mystical/insight experiences to improved outcomes via increases in psychological flexibility, the study hypothesised that (H1) acute mystical-type, challenging and insight effects would be associated with changes in racial trauma symptoms, (H2) acute effects would be directly related to changes in psychological flexibility, (H3) changes in psychological flexibility would be directly related to changes in racial trauma symptoms, and (H4) psychological flexibility would mediate the relationships between acute effects and trauma symptom change.

This analysis used cross-sectional data drawn from a larger observational online survey of POC. Eligibility required participants to be at least 18 years old, read English, have had a psychedelic experience that produced psychoactive effects and reported relief from racial discrimination after that experience, and currently reside in Canada or the United States. Recruitment occurred in September 2019 through Qualtrics research panels; respondents completed a secure forced-response questionnaire and received panel incentives. After quality-control checks (poor responder, bot, duplicate detection), the final sample comprised 313 participants with no missing data due to mandatory item response. Measures included demographics and a range of validated scales. Racial discrimination before the psychedelic experience was assessed with the General Ethnic Discrimination Scale. Acute psychedelic effects were measured retrospectively using the Psychological Insight Questionnaire (PIQ, 23 items), Mystical Experience Questionnaire (MEQ, 30 items), and Challenging Experience Questionnaire (CEQ, 26 items); internal consistency for these scales was excellent (Cronbach's alpha 0.95–0.97). Psychological flexibility was assessed with the Acceptance and Action Questionnaire-II (AAQ-II, 7 items) administered as a before-and-after then-test, and a change score was computed and sign-reversed so positive values indicate increased psychological flexibility (alpha = 0.89 pre and post). Trauma symptoms related to discrimination were assessed with the Trauma Symptoms of Discrimination Scale, queried for the 30 days before and the 30 days after the referent psychedelic experience; change scores were computed (alpha = 0.96 before, 0.95 after). Analyses proceeded in three stages. Descriptive statistics and tests of normality were calculated, followed by Pearson and point-biserial correlations among primary variables (age, sex, acute insight, mystical-type, challenging effects, trauma symptom change, psychological flexibility change, race groups). Hypothesis 1 was evaluated with a multiple linear regression predicting trauma symptom change scores from acute mystical-type, challenging, and insight effects while controlling for the summed ethnic discrimination events. Hypotheses 2–4 were tested with a path analysis (maximum likelihood estimation) examining direct effects of acute effects on psychological flexibility change, direct effects of psychological flexibility change on trauma symptom change, and indirect (mediated) paths. Race was examined but excluded from models because it was uncorrelated with other variables. Analyses used SPSS v27 and MPlus v8.0. The study employed a one-group pretest/posttest (then-test) approach for retrospective pre/post assessment of symptoms.

Sample characteristics: The analytic sample included 313 participants (mean age 33.1, SD = 11.2), 57% female. Racial composition was diverse: 32% identified as Black/African heritage, 29% as East/South Asian or Asian American/Canadian, 18% as Native American or Indigenous Canadian, and 21% as Native Hawaiian, Pacific Islander, or other. Reported index substances were LSD (36%), psilocybin/mushrooms (37%), and MDMA (27%); approximately 56% reported a moderately high or high dose. Bivariate associations showed that mystical-type and insight effects were strongly positively correlated, and insight showed a weak positive correlation with challenging effects. Greater intensity of acute insight and mystical-type experiences correlated moderately with increases in psychological flexibility and with decreases in trauma symptoms. Psychological flexibility change was negatively correlated with trauma symptoms measured both before (R = -0.66, p < .001) and after (R = -0.61, p < .001) the psychedelic experience. Regression results (controlling for sum of ethnic discrimination events, mean = 31.95, SD = 17.23) indicated the overall model predicting trauma symptom change was significant (p < .001) and accounted for 23% of variance (supporting H1). Within this model, greater intensity of insight effects and lower intensity of challenging effects were significantly associated with decreases in trauma symptoms; mystical-type effects were not a significant predictor. Reported central tendency for acute effects were: mystical M = 3.03 (SD = 1.03), challenging M = 1.52 (SD = 1.17), insight M = 2.78 (SD = 1.01). Mean trauma symptom change was -8.64 (SD = 16.19), range -62 to 63. Path analysis results supported H2–H4. Controlling for ethnic discrimination, greater insight intensity was directly related to mean increases in psychological flexibility (β = 0.34, p < .001), and lower challenging intensity was also directly related to increases in psychological flexibility (β = -0.32, p < .001); mean increase in psychological flexibility was 0.93 (SD = 1.55, range -5.14 to 6). Changes in psychological flexibility were directly related to changes in racial trauma symptoms (β = -0.58, p < .001). Indirect (mediated) effects were significant: insight → psychological flexibility → trauma change (β = 0.20, SE = 0.04, p < .001) and challenging → psychological flexibility → trauma change (β = -0.18, SE = 0.03, p < .001), indicating partial mediation. Model fit indices were excellent: χ2 = 1.865 (p = .394), RMSEA = 0.000 (90% CI .00, .11), CFI = 1.00, SRMR = 0.008.

Davis and colleagues interpret the results as providing support for the hypothesised relationships: greater acute psychological insight and lower intensity of challenging psychedelic experiences were associated with reductions in racial trauma symptoms, and these relationships were partially mediated by increases in psychological flexibility. The absence of a significant relationship for mystical-type effects is noted; the authors suggest this may indicate mystical experiences are less relevant to racial-trauma outcomes in POC or that the proportion of MDMA users in the sample (about one-quarter) — a substance that typically produces fewer mystical-type effects — may have attenuated that association. A small positive correlation between challenging and insight effects is highlighted and the authors suggest that heightened negative arousal during challenging experiences may coexist with or even facilitate insights, but they emphasise that causal inferences cannot be drawn from these data. Several limitations are acknowledged. The cross-sectional, retrospective design is vulnerable to recall bias and does not allow definitive causal claims; participant responses could not be independently verified and the sample was self-selected via online panels, introducing possible selection bias and limiting generalisability. The purposive recruitment of individuals who reported benefit after psychedelic use precludes estimating prevalence of positive outcomes or characterising adverse outcomes. The authors further note the lack of multiple prospective assessments limits strength of mediation claims; to mitigate this they used a then-test pre/post approach, but they recommend prospective clinical trials. Measurement concerns are discussed: recent critiques of the AAQ-II raise questions about its convergent and discriminant validity and potential stronger associations with negative affect or psychopathology than with core psychological flexibility processes. Finally, the authors point out that subjective measures (MEQ, PIQ, CEQ) might map onto underlying neurobiological mechanisms, which should be tested in laboratory-based studies. In terms of implications, the authors argue the findings add to emerging evidence that psychological flexibility may be an important mechanism by which acute psychedelic experiences translate into sustained mental-health benefits, and that this construct merits focused research in POC. They suggest psychological flexibility could be incorporated as a therapeutic target in psychedelic-assisted interventions tailored for POC, while noting psychedelics would not directly address systemic determinants of health disparities. The authors call for more inclusive research and longitudinal clinical trials among BIPOC to test these pathways.

The authors conclude that, despite study limitations, the findings indicate psychedelics may confer benefits in reducing racial trauma symptoms among POC and that increases in psychological flexibility appear to be an important mediator of these effects. They emphasise the need for expanded research that includes racial and ethnic minorities to develop culturally informed psychedelic-assisted interventions for underserved communities, while acknowledging that such interventions do not substitute for addressing broader systemic contributors to health disparities.